posts tagged as pharmaceuticals


Negative Side Effects of Tax Reform for Life Sciences

The tax benefits of orphan drugs, R&D expenses and employee fringe benefits lose weight under the new tax law. How will tax implications impact your organizational strategies? read more


Maximizing Data Integrity to Mitigate Government Pricing Risk

In an era of pricing transparency and increasing calls for even greater government pricing regulation, government pricing risk is heightened for drug manufacturers. Ensuring data integrity is key. Discover ways to monitor and review... read more


By Steven Shill | April 20, 2018

The Growing Diabetes Market in China and How U.S. Healthcare Orgs Can Break into It

The diabetes market in China has undergone rapid growth over the past few decades that is expected to continue. However, despite the ripe opportunity, U.S. healthcare organizations have had difficulty breaking into this market. How can... read more


BDO’s Healthcare Rx Newsletter: Future of Healthcare Lies in the Data

In our revamped newsletter, BDO’s Healthcare Rx, we look at how three foundational shifts and five revolutionary forces are changing healthcare. Where do opportunities lie? One clue—start with Medicare Advantage. read more


3 Foundational Shifts in Healthcare

Three foundational shifts are behind major healthcare developments: mandates to choice, regulation to competition, and subsidies to actuarial soundness. Here’s what they mean for healthcare’s stakeholders. read more


What Life Sciences Companies Need to Know About Tax Reform

To help organizations navigate the issues most impactful and urgent to the life sciences industry, we’ve prepared a summary of the industry implications based on the signed legislation. read more


Consumers, Healthcare Orgs Unaligned on Value-Based Drug Pricing: BDO/NEJM Catalyst Survey

When it comes to aligning care outcomes with pricing, consumers and healthcare providers are, well, unaligned, a new survey from BDO and the NEJM Catalyst reveals. read more


Pharma Supply Chains: Steady or Susceptible? BDO Life Sciences RiskFactor Report

It’s not the risks that are unfamiliar to life sciences companies causing consternation—it’s the changes to the operating environment. With regulatory tailwinds promising to boost innovation, and pricing and value-based care... read more


Taking the Temperature of Healthcare M&A Activity

Despite 21 megadeals, healthcare M&A levels declined slightly in the first half of 2017. Still, there’s reason for optimism ahead as strategic and private equity buyers alike are in a strong position to move in attractive sectors. Read... read more


What Healthcare Organizations Should Know About Petya-like Cyberattack

The global cyberattack potentially modeled after Petya did not inflict as much damage to the healthcare sector as WannaCry, but healthcare organizations should still be mindful. Here’s what they need to know. read more